Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 11/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.62 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.62 |
| ▸ | CDC42BPB | Q9Y5S2 | 9/20 | 0.62 |
| ▸ | CDC42BPA | Q5VT25 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30543157 | 1.00 | LRRK2 (1.00) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL3561097 | 0.79 | LRRK2 (0.66) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL26930286 | 0.79 | LRRK2 (0.66) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL30674338 | 0.79 | LRRK2 (0.66) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL16190651 | 0.79 | LRRK2 (0.67) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL3565489 | 0.78 | LRRK2 (0.72) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL16785960 | 0.77 | LRRK2 (0.62) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL20744117 | 0.77 | ROCK2 (1.00) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL30668734 | 0.77 | ROCK2 (1.00) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL25323944 | 0.76 | LRRK2 (0.60) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-11-27 | — | — | US | disclosed |
| EP-4536657-A1 | LATS INHIBITORS AND USES THEREOF | The USA, as represented by The Secretary, Department of Health and Human Services (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023239727-A1 | LATS INHIBITORS AND USES THEREOF | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239727-A1 | LATS INHIBITORS AND USES THEREOF | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-111278840-B | Pyrrolo [2,3-B ] pyridine compounds and their use for the treatment of cancer | 癌症研究科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| EP-4214214-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-07-26 | — | — | EP | disclosed |
| EP-4214199-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-07-26 | — | — | EP | disclosed |
| CN-116171280-A | Casein kinase 1 delta modulators | 詹森药业有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20100010037-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | VERNALIS (R&D) LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-2057155-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | Vernalis (R&D) Limited (GB) | 2009-05-13 | — | — | EP | disclosed |
| CN-101223168-A | Heterocyclic JANUS kinase 3 inhibitors | ASTELLAS PHARMA INC (JP) | 2008-07-16 | — | — | CN | disclosed |
| EP-1910358-A2 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | Astellas Pharma Inc. (JP) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008025947-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025947-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2008-03-06 | — | — | WO | disclosed |
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007007919-A2 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK2A1 | LRRK2 787/4885ROCK2 958/4885ROCK1 516/4885 |
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | LATS2, LATS1, AKT1S1 | LRRK2 41/4885ROCK2 868/4885ROCK1 1015/4885 |
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK1G1 | LRRK2 863/4885ROCK2 1072/4885ROCK1 607/4885 |
| US-20100010037-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | LRRK2 2502/4885ROCK2 294/4885ROCK1 153/4885 |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK2, JAK1 | LRRK2 444/4885ROCK2 162/4885ROCK1 75/4885 |
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | LRRK2 162/4885ROCK2 680/4885ROCK1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.